Overview

This video features Prof. Paolo Ghia discussing key findings from the CLL‑321 manuscript, focusing on the clinical relevance of pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a covalent BTK inhibitor. The discussion highlights treatment challenges, efficacy outcomes, and the potential role of Jaypirca in current CLL management in alignment with the approved Saudi label.

This Class for

Clinical Pharmacy
Pharmacy
Physician
Resident / Fellow

What I will learn?

By the end of this video, the HCP will be able to:

Understand the ongoing treatment challenges in relapsed/refractory CLL following prior covalent BTK inhibitor therapy.
Review key efficacy and safety results from the CLL‑321 manuscript.
Recognize the clinical positioning of pirtobrutinib based on trial evidence.
Apply trial insights to appropriate Jaypirca‑eligible CLL patient profiles within the approved indication.

Disclaimer

This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)

For adverse events and safety reporting: email: [email protected]

24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

For Lilly product information: email: [email protected]

For further information, please contact:

Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: [email protected]

CMAT-17531

Content